Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05335122 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)
A Phase 2 study, sponsored by Ocular Therapeutix.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT05335122 is a Phase 2 study that has completed, run by Ocular Therapeutix. The registered enrollment target is 83 participants.
The verdict
NCT05335122, a Phase 2 study, has completed, sponsored by Ocular Therapeutix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
To assess efficacy, and safety of a single sustained release dose of the OTX-TIC drug product (2 travoprost dose strengths) in subjects with Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
Interventions
- DRUG Durysta, Bimatoprost Intracameral Implant 10 µg
- DRUG OTX-TIC low dose Travoprost Intracameral Implant
- DRUG OTX-TIC high dose Travoprost Intracameral Implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2022-03-16 |
| Est. Completion | 2025-01-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05335122
The ClinicalTrials.gov registry entry for NCT05335122 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocular Therapeutix, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Durysta, Bimatoprost Intracameral Implant 10 µg is the first listed.
NCT05335122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05335122 about?
NCT05335122 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)". To assess efficacy, and safety of a single sustained release dose of the OTX-TIC drug product (2 travoprost dose strengths) in subjects with Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
What is the current status of trial NCT05335122?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2022-03-16. Estimated completion is 2025-01-24.
What interventions are being tested in trial NCT05335122?
The interventions under investigation include: Durysta, Bimatoprost Intracameral Implant 10 µg (DRUG), OTX-TIC low dose Travoprost Intracameral Implant (DRUG), OTX-TIC high dose Travoprost Intracameral Implant (DRUG).
Who is sponsoring clinical trial NCT05335122?
This trial is sponsored by Ocular Therapeutix, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.